Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates - GBI Research Reports

Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates

Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates - GBI Research Reports
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
Published Feb 29, 2012
79 pages — Published Feb 29, 2012
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Researchs new report, Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes overall pharmaceutical and outsourcing market structure in the Czech Republic. The report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Czech pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The Czech Republic pharmaceutical market is one of the most attractive markets in Central and Eastern Europe. The availability of cost effective skilled labour, high quality infrastructure and EU harmonious regulations are the main reasons for the fast growth of the Czech pharmaceutical industry. Most local drug manufacturers and distributors are owned by big international pharmaceutical firms. GBI Research valued the Czech pharmaceutical market at $3.1 billion in 2010, which grew with a compound annual growth rate (CAGR) of 11.7% from 2004 to 2010. The Czech healthcare sector will witness many new healthcare reforms in the coming years, with the primary objective of reducing growing drug expenditure. In response to these healthcare policies, the Czech pharmaceutical market is expected to witness a lower growth rate in forecast period.

GBI Research has analyzed that in 2011, generics had a share of over 50% of the Czech pharmaceutical market. Czech government reforms encourage the manufacture and use of generic drugs, in an attempt to limit drug expenditure and provide low cost-effective public healthcare. Government healthcare policies, coupled with numerous active generic manufacturing companies in the country, will increase the share of generics in the market during the forecast period.

The Czech Republic is showing a moderate recovery from the economic downturn in 2009; increased industrial outputs and government structural reforms in various sectors including healthcare have contributed to the growth. GBI Research analyzed that the new healthcare reform policy which is expect to be implemented from 2012, with elements of standard and above standard care, in which patients pay more for above standard (expensive drugs and services) care and an increase in co-payments from the patients, reduces healthcare affordability for individual patients and will pose a major challenge to the Czech pharmaceutical market.

Scope

- Overall pharma, biotech and outsourcing market structure in Czech Republic
- Czech Republic pharmaceutical market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights.
- Czech Republic CRO market growth.
- Analysis of the leading segments within the Czech Republic pharmaceutical industry.
- Key market drivers and restraints that have a significant impact on the Czech Republic pharmaceutical market.
- Competitive benchmarking of leading companies in pharmaceutical and CRO markets.
- Key M&A activities and strategic partnership deals that have taken place between 2009 and mid 2011.

Reasons to buy

- Develop market entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of the countrys pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate an

  
Source:
Document ID
GBIHC200MR
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents35
  List of Tables51
  List of Figures62
Emerging Pharmaceutical Market - Czech Republic - Introduction81
  GBI Research Report Guidance81
Emerging Pharmaceutical Market - Czech Republic - Industry Characterstics916
  Market Size and Market Forecast91
  Market Share by Indication101
  Branded versus Generic Share111
  R&D Expenditure Innovations113
  Top Pharmaceutical Companies141
    Zentiva (Sanofi)141
    PLIVA-Lachema (Teva)141
    Teva Czech Industries s.r.o141
    Lonza Biotec (Lonza)141
    FARMAK151
    Walmark151
    Pfizer151
    Novartis151
    Merck161
    AstraZeneca161
    GlaxoSmithKline161
  Foreign Direct Investment171
  Marketing Distribution Channel182
  Exports and Imports201
    Exports201
    Imports211
  Market Drivers and Restraints221
    Drivers221
      Established Generic Industry221
      High Quality Infrastructure221
      Increasing Ageing Population231
      Rising Pharmaceutical Product Exports231
    Restraints231
      Government Reforms Plans To Reign Drug Expenses231
      Specific Pricing and Reimbursement Levels241
  Industry Analysis241
Emerging Pharmaceutical Market - Czech Republic - Macroeconomic Environment2522
  Demographic Analysis251
    Population Size, Growth, and Structure253
      Life Expectancy at Birth282
    Disease Overview in Czech Republic301
      Number of Deaths Occurring by Major Diseases in Czech Republic301
      Cardiovascular Diseases (CVD)311
      Cancer321
      Respiratory Diseases331
      Diabetes341
  GDP354
  Per Capita Income391
  Healthcare Expenditure401
    Context402
    Analytical Framework421
  Healthcare Infrastructure431
    Context431
    Analytical Framework441
      Number of Active Healthcare Professionals451
      Number of Beds452
Emerging Pharmaceutical Market - Czech Republic - Healthcare Regulation479
  Pharmaceutical Regulation in Czech Republic471
    Healthcare System Structure471
    Recent Healthcare Reform Plans471
  Intellectual property Rights (IPR) and entry of Generics481
  Health Insurance Coverage491
    Public Insurance Coverage501
    Private Insurance Coverage501
  Pricing and Reimbursement501
    Pricing511
    Reimbursement511
  New Drug Approval Process521
  Clinical Trials531
    Context531
    Analytical Framework532
  Regulatory Bodies551
    State Institute for Drug Control551
    Czech Ministry of Health551
Emerging Pharmaceutical Market - Czech Republic - Industry Trends566
  Mergers and Acquisitions561
    Deals by Year561
    Deals by Type571
    Deal by Value581
    Top M&A Deals591
      Sanofi-Aventis Acquires Majority Stake in Zentiva591
      Zentiva Acquires Remaining 25% Stake In Eczacibasi-Zentiva591
      Recordati Acquires HERBACOS-BOFARMA591
      Cryo-Save Group Acquires Sejtbank Egeszsegugyi Szolgaltato Korlatolt Felelossegu Tarsasag And Cryo-Save601
  Licensing Agreements601
    Deals by Year601
    Top Three Licensing Deals611
      Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharmaceuticals For Episil611
      AbCheck Enters Into Licensing Agreement With Celexion611
      Kadmon Pharmaceuticals Enters Into Licensing Agreement with Valeant Pharmaceuticals for Ribavirin611
Emerging Pharmaceutical Market - Czech Republic - CRO Industry6215
  Clinical Research Organization (CRO)621
  CRO Company Profiles - Foreign Players621
    Quintiles621
      Business Description631
    PPD641
      Business Description641
    Covance651
      Business Description651
    Inc Research661
      Business Description661
    PAREXEL671
      Business Description671
    Chiltern681
      Business Description681
    MEDPACE691
      Business Description691
    PRA International701
      Business Description701
  CRO Company Profiles - Domestic Players711
    CEPHA711
      Business Description711
    KCR721
      Business Description721
    A-Pharma731
      Business Description731
    EastHORN741
      Business Description741
    Prague Clinical Services751
      Business Description751
    PHARMNET761
      Business Description761
Emerging Pharmaceutical Market - Czech Republic - Appendix773
  Market Definitions771
  Abbreviations771
  Research Methodology772
    Industry Performance781
    Macroeconomic Environment781
    Healthcare Regulations781
    Industry Trends781
  Contact Us781
  Disclaimer781
  Sources791

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates" Feb 29, 2012. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Pharmaceutical-Market-Czech-Republic-Planned-Healthcare-Reform-Plans-Forecast-to-Slow-Growth-Rates-2115-385>
  
APA:
GBI Research Reports. (2012). Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates Feb 29, 2012. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Emerging-Pharmaceutical-Market-Czech-Republic-Planned-Healthcare-Reform-Plans-Forecast-to-Slow-Growth-Rates-2115-385>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.